Azimilide di hydrochloride

Product Details
Formula	C23H30Cl3N5O3
Molecular Weight	530.88
Appearance	Solid
Purity	98.02%
Smiles String	O=C1N(CCCCN2CCN(C)CC2)C(CN1/N=C/C3=CC=C(C4=CC=C(Cl)C=C4)O3)=O.[H]Cl.[H]Cl

Storage & Handling
Shipping	Room temperature.
Storage	4 °C, sealed storage, away from moisture *In solvent : -80 °C, 6 months; -20 °C, 1 month (sealed storage, away from moisture)

Azimilide (NE-10064) dihydrochloride is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes. IC50 value: Target: in vitro: Azimilide dihydrochloride blocked HERG channels at 0.1 and 1 Hz with IC50s of 1.4 microM and 5.2 microM respectively. Azimilide dihydrochloride blockade of HERG channels expressed in Xenopus oocytes and I(Kr) in mouse AT-1 cells was decreased under conditions of high [K+]e, whereas block of slowly activating I(Ks) channels was not affected by changes in [K+]e . Azimilide dihydrochloride suppressed the following currents (Kd in parenthesis): IKr (< 1 microM at -20 mV), IKs (1.8 microM at +30 mV), L-type Ca current (17.8 microM at +10 mV), and Na current (19 microM at -40 mV). Azimilide dihydrochloride was a weak blocker of the transient outward and inward rectifier currents (Kd > or = 50 microM at +50 and -140 mV, respectively). Azimilide dihydrochloride blocked IKr, IKs, and INa in a use-dependent manner. Furthermore, azimilide reduced a slowly inactivating component of Na current that might be important for maintaining the action potential plateau in canine ventricular myocytes . In guinea pig ventricular myocytes, Azimilide (0.3-3 microM) dihydrochloride significantly prolonged action potential duration (APD) at 1 Hz. At 3 Hz, Azimilide (0.3-1 microM) dihydrochloride increased APD only slightly, and at 10 microM decreased APD and the plateau potential. Azimilide dihydrochloride potently blocked the rapidly activating component of the delayed rectifier, IKr (IC50 0.4 microM), and inhibited IKs (IC50 3 microM) with nearly 10-fold less potency . in vivo: Azimilide (10 mg/kg intravenously, i.v.) dihydrochloride reduced (p < 0.05) the incidence (8 of 12) of PES-induced ventricular tachycardia (VT). The cycle length of induced VT was not prolonged by Azimilide (0.245 +/- 0.046 s predrug vs. 0.301 +/- 0.060 s postdrug) dihydrochloride. Azimilide dihydrochloride increased ventricular effective refractory period (VERP 166 +/- 5 ms predrug vs. 194 +/- 13 ms postdrug, p = 0.013), prolonged QTc interval (310 +/- 12 ms predrug vs. 350 +/- 16 ms postdrug, p = 0.004) and prolonged the effective refractory period (ERP) of noninfarcted myocardium (p = 0.045) .

! For research use only. Not intended for any clinical use.